A groundbreaking discovery by researchers has brought hope for a safer alternative to opioids for treating acute and chronic pain. SBI-810, a novel non-opioid chemical, has demonstrated potent analgesic effects in animal studies without the negative side effects associated with opioids.
SBI-810’s dual impact on both the central and peripheral nervous systems effectively reduces pain while minimizing the risk of opioid-induced complications such as addiction, constipation, and withdrawal symptoms. This innovation offers a new therapeutic path to develop medications for postoperative pain, inflammation, and neuropathy.
The compound works by selectively activating specific signaling pathways through biased allosteric modulators (BAMs), enhancing therapeutic effects while minimizing side effects. SBI-810 binds to neurotensin receptors (NTSR1) and recruits β-arrestin-2, bypassing G-protein pathways associated with adverse effects.
In mouse models, SBI-810 raises pain thresholds and effectively reduces various types of pain, including postoperative pain, inflammatory pain, and neuropathic pain. The compound’s potential is underscored by its ability to counter acute opioid-induced reward behaviors and lessen opioid-related side effects.
Compared to existing treatments, SBI-810 offers several advantages, including its dual action on the central and peripheral nervous systems. Unlike selective peripheral inhibitors, SBI-810 targets both systems, making it effective in treating different types of pain. Additionally, it addresses cognitive impairment associated with gabapentin and tackles opioid-related challenges.
Duke University has filed two U.S. patent applications for novel non-opioid pain treatments using SBI-810 and its mechanism of action. However, further studies are needed to explore the compound’s potential in other disease contexts and clarify its effects on brain regions involved in pain perception and reward.
Source: https://www.insideprecisionmedicine.com/topics/translational-research/non-opioid-compound-shows-acute-and-chronic-pain-relief-potential